SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

PARSIPPANY, N.J., May 05, 2025--(BUSINESS WIRE)--Ferring Pharmaceuticals presented initial findings from the investigational Phase 3b multi-center, single-arm CDI-SCOPE study evaluating the safety and ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals is celebrating the second anniversary of the launch of REBYOTA ® (fecal microbiota, live – jslm), the first microbiome-based therapy approved ...